UK report calls for cooperation on population genotypingBMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7185.692c (Published 13 March 1999) Cite this as: BMJ 1999;318:692
- Tessa Richards
The government must work with the pharmaceutical industry, healthcare providers, insurance companies, and the public to define the policy issues posed by the rapid advances in genetics and to agree terms under which population genotyping might proceed, according to a report from the School of Public Policy in London.
Currently, public policy lags behind the science, and the social and ethical issues posed by widespread genotyping, particularly with respect to the privacy and confidentiality of genetic data, are not being actively confronted. Meanwhile, the pace is being set-as the recent …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial